Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2007-08-16 Proxy Solicitation & In…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Annual General Meeting / Special Meeting
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a proxy form and form of instruction for voting at the Annual General Meeting (AGM) and Extraordinary General Meeting (EGM) of XTL Biopharmaceuticals Ltd. It includes resolutions to receive the Annual Report and Accounts, appoint auditors, re-appoint directors, increase share capital, and cancel the listing of shares. The document is not the Annual Report itself but a voting instruction related to the meetings. It is a material provided to shareholders to enable voting at the AGM and EGM, which fits the definition of Proxy Solicitation & Information Statement (PSI). The document length (8298 characters) and content confirm it is not a brief announcement or a full report but a proxy solicitation document.
2007-08-16 Hebrew (modern)
Annual General Meeting / Special Meeting
AGM Information Classification · 95% confidence The document is a notice of an Annual General Meeting (AGM) and an Extraordinary General Meeting (EGM) for XTL Biopharmaceuticals Ltd. It includes details about the meeting dates, agenda items such as receipt of financial statements, appointment of auditors, re-appointment of directors, increase of share capital, and cancellation of listing on the UK Official List. The document contains proxy forms and instructions for shareholders to vote. It is a formal meeting notice and proxy solicitation document rather than the actual financial statements or detailed reports. The content aligns with materials typically provided to shareholders ahead of an AGM and EGM to inform them and solicit their votes. Therefore, the document fits the category of AGM Information (AGM-R).
2007-08-16 Hebrew (modern)
Annual General Meeting / Special Meeting
AGM Information Classification · 99% confidence The document explicitly mentions 'Annual General Meeting / Special Meeting' and provides details about the date (25/09/2007), time, and location of the meeting. It also references attached documents like a 'CIRCULARFINAL_isa.pdf' and a 'FINALProxyandFOI_isa.pdf', which are typical components of AGM materials. This strongly indicates the document is related to the Annual General Meeting. Therefore, the appropriate classification code is AGM-R.
2007-08-16 English
AGM Information 2007
AGM Information Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., dated August 15, 2007. It announces that notices for the Annual General Meeting (AGM) and Extraordinary General Meeting (EGM) have been posted to shareholders. The document details the agenda items for the upcoming AGM and EGM, including receipt of annual reports, reappointment of auditors and directors, increase in share capital, and delisting from the UK listing authority. The document is an announcement of meeting notices and related proposals, not the actual AGM materials or annual report itself. The document length is 3903 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of AGM Information (AGM-R), as it relates to the AGM and EGM notices and materials shared with shareholders.
2007-08-15 English
Interim / Quarterly Report 2007
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filing by XTL Biopharmaceuticals Ltd., which is a report of a foreign private issuer pursuant to SEC rules. It contains detailed financial results for the six months ended June 30, 2007, including consolidated balance sheets, statements of operations, changes in shareholders' equity, and cash flows. The presence of unaudited interim financial statements for a six-month period indicates this is an interim or quarterly report. The document is about 15,000 characters long, which is substantial and contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2007-08-15 English
Immediate report on other matter
AGM Information Classification · 95% confidence The document is an announcement regarding the posting of notices to shareholders for an upcoming Annual General Meeting (AGM) and Extraordinary General Meeting (EGM). It details the agenda items for the meetings, including receipt of the annual reports, reappointment of auditors and directors, increase in share capital, and delisting from the UK Official List. The document does not contain the actual annual report or financial statements but rather informs shareholders about the meetings and their agenda. The document length is short (2184 characters), and it serves as a notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including notices and meeting agendas.
2007-08-15 Hebrew (modern)

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.